656804-69-2Relevant academic research and scientific papers
Benzodioxoles: Novel cannabinoid-1 receptor inverse agonists for the treatment of obesity
Alig, Leo,Alsenz, Jochem,Andjelkovic, Mirjana,Bendels, Stefanie,Bénardeau, Agnès,Bleicher, Konrad,Bourson, Anne,David-Pierson, Pascale,Guba, Wolfgang,Hildbrand, Stefan,Kube, Dagmar,Lübbers, Thomas,Mayweg, Alexander V.,Narquizian, Robert,Neidhart, Werner,Nettekoven, Matthias,Plancher, Jean-Marc,Rocha, Cynthia,Rogers-Evans, Mark,R?ver, Stephan,Schneider, Gisbert,Taylor, Sven,Waldmeier, Pius
, p. 2115 - 2127 (2008/12/22)
The application of the evolutionary fragment-based de novo design tool TOPology Assigning System (TOPAS), starting from a known CB1R (CB-1 receptor) ligand, followed by further refinement principles, including pharmacophore compliance, chemical tractabili
NOVEL BENZODIOXOLES
-
Page 110, (2008/06/13)
The present invention relates to compound of formula (I) Wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases, which are associated with the modulation of CB1 receptors.
Bis-imidazolyl-bisphenylmethane and salts thereof
-
, (2008/06/13)
Bis-imidazolyl-bisphenylmethane derivatives and pharmaceutically acceptable non-toxic salts thereof are useful as antimycotics especially against dermatomycosis caused by Trichophyton and Microsporium species and also against yeast infections of the skin and internal organs.
